Jul 05, 2022
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
Jun 15, 2022
PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections
Jun 06, 2022
PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
Jun 02, 2022
PolyPid to Present at the JMP Securities 2022 Life Sciences Conference
Jun 01, 2022
PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects
May 31, 2022
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery
May 23, 2022
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
May 11, 2022
PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results
Apr 27, 2022
PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022
Apr 25, 2022
PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine
Displaying 1 - 10 of 19